ELIAS Animal Health Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$430K
- Investors
-
5
ELIAS Animal Health General Information
Description
Operator of a medical biotechnology company intended to provide cancer treatment for pets. The company helps harness the power of the dog's immune system to eliminate cancer by utilizing adoptive cell therapy to deliver an army of activated T-cells that kill cancer cells, enabling veterinarians and pet owners to have access to a new approach to cancer treatment.
Contact Information
Website
www.eliasanimalhealth.comCorporate Office
- 10049 Lakeview Avenue
- Lenexa, KS 66219
- United States
Corporate Office
- 10049 Lakeview Avenue
- Lenexa, KS 66219
- United States
ELIAS Animal Health Timeline
ELIAS Animal Health Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 29-Dec-2025 | $430K | Completed | Generating Revenue | ||
| 7. Later Stage VC (Series A) | 10-Apr-2024 | Completed | Clinical Trials - General | |||
| 6. Later Stage VC | 21-Sep-2022 | Completed | Clinical Trials - General | |||
| 5. Later Stage VC | 13-May-2020 | Completed | Clinical Trials - General | |||
| 4. Later Stage VC | 22-Jan-2020 | Cancelled | Clinical Trials - General | |||
| 3. Seed Round | 10-May-2017 | Completed | Clinical Trials - General | |||
| 2. Seed Round | 26-Mar-2015 | $2M | $12M | Completed | Clinical Trials - General | |
| 1. Seed Round | $10M | $10M | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
ELIAS Animal Health Patents
ELIAS Animal Health Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025259866-A2 | Combination of chemotherapy, cancer cell vaccine and adoptive cell therapy | Pending | 14-Jun-2024 | ||
| WO-2025259866-A3 | Combination of chemotherapy, cancer cell vaccine and adoptive cell therapy | Pending | 14-Jun-2024 | ||
| EP-4727562-A1 | Use of cd200ar-l for enhancing adoptive t-cell therapy | Pending | 16-Jun-2023 | ||
| WO-2024259195-A1 | Use of cd200ar-l for enhancing adoptive t-cell therapy | Inactive | 16-Jun-2023 | A61K40/11 |
ELIAS Animal Health Signals
ELIAS Animal Health Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| eGrowth Ventures | Not-For-Profit Venture Capital | Minority | ||
| Kansas Bioscience Authority | Government | Minority | ||
| Mid America Angels | Angel Group | Minority | ||
| Women's Capital Connection | Angel Group | Minority | ||
| Angel (individual) | Minority |
ELIAS Animal Health FAQs
-
When was ELIAS Animal Health founded?
ELIAS Animal Health was founded in 2014.
-
Where is ELIAS Animal Health headquartered?
ELIAS Animal Health is headquartered in Lenexa, KS.
-
What is the size of ELIAS Animal Health?
ELIAS Animal Health has 8 total employees.
-
What industry is ELIAS Animal Health in?
ELIAS Animal Health’s primary industry is Other Services (B2C Non-Financial).
-
Is ELIAS Animal Health a private or public company?
ELIAS Animal Health is a Private company.
-
What is ELIAS Animal Health’s current revenue?
The current revenue for ELIAS Animal Health is .
-
How much funding has ELIAS Animal Health raised over time?
ELIAS Animal Health has raised $31.1M.
-
Who are ELIAS Animal Health’s investors?
eGrowth Ventures, Kansas Bioscience Authority, Mid America Angels, Women's Capital Connection, and have invested in ELIAS Animal Health.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process